Stockpolly
Search
Delisting riskEarnings are out
BLRX · NASDAQ · Biotechnology

BioLineRx (ADR) (BLRX)

Builds oncology assets around APHEXDA royalties and GLIX1 clinical development.

$2.66
Pre-market−0.00 (−0.08%)
At close$2.66(−3.62%)
Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions13 holders · as of Mar 31, 20260.45%19.6K ADS
Otherremainder99.55%4.33M ADS

4.35M ADS as of Aug 25, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

The share count has not been confirmed by a second filing; stakes use it as it stands.

Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
XTX Topco LtdInstitution
0.25%10,941 ADS13Fas of Mar 31, 2026
Rhumbline AdvisersInstitution
0.05%2,353 ADS13Fas of Mar 31, 2026
BNP Paribas Arbitrage, SNCInstitution
0.04%1,800 ADS13Fas of Mar 31, 2026
Wells Fargo & Company/MNInstitution
0.04%1,750 ADS13Fas of Mar 31, 2026
Citigroup IncInstitution
0.04%1,728 ADS13Fas of Mar 31, 2026
UBS Group AGInstitution
0.01%529 ADS13Fas of Mar 31, 2026
Nemes Rush Group LLCInstitution
0.01%250 ADS13Fas of Mar 31, 2026
Newedge Advisors, LLCInstitution
0.00%107 ADS13Fas of Mar 31, 2026
Morgan StanleyInstitution
0.00%100 ADS13Fas of Mar 31, 2026
Advisor Group Holdings, Inc.Institution
0.00%26 ADS13Fas of Mar 31, 2026
Rockefeller Capital Management L.P.Institution
0.00%12 ADS13Fas of Mar 31, 2026
Danske Bank A/SInstitution
0.00%2 ADS13Fas of Mar 31, 2026
Altium Capital Growth GP, LLCStrategic
—3.70% of class, as filed—13G/Afiled Feb 16, 2021 ↗
Armistice Capital, LLCStrategic
—4.99% of class, as filed—13Gfiled Jun 5, 2020 ↗
BVF Partners L.P.Institution
—5.30% of class, as filed—13G/Afiled Jun 2, 2020 ↗
Highbridge Capital Management, LLCStrategic
—7.20% of class, as filed—13Gfiled Aug 14, 2025 ↗
Lepu (Hong Kong) Co., LimitedStrategic
—9.50% of class, as filed—13D/Gfiled Oct 26, 2023 ↗
Mitchell P. KopinInsider
—1.00% of class, as filed—13G/Afiled Feb 11, 2022 ↗
Novartis Pharma AGStrategic
—1.00% of class, as filed—13G/Afiled Feb 16, 2021 ↗
Richard MashaalInsider
—0.77% of class, as filed—13G/Afiled Feb 12, 2021 ↗
Aharon Schwartz1Insiderdirector
——Form 4filed Mar 30, 2026 ↗
Philip A. Serlin1Insiderofficer: Chief Executive Officer
——Form 4filed Mar 27, 2026 ↗
Mali Zeevi1Insiderofficer: Chief Financial Officer
——Form 4filed Mar 18, 2026 ↗
  1. This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

13 holders · 19.6K shares · 2 new positions · 3 increased · 3 reduced · 2 closed

HolderShares% outstandingChg q/qFiled
XTX Topco Ltd10.9K0.25%+10.9KnewMay 15, 2026
Rhumbline Advisers2.4K0.05%−1.0KMay 12, 2026
BNP Paribas Arbitrage, SNC1.8K0.04%+300May 12, 2026
Wells Fargo & Company/MN1.8K0.04%0Jul 8, 2026
Citigroup Inc1.7K0.04%−310May 11, 2026
UBS Group AG5290.01%−1.4KMay 5, 2026
Nemes Rush Group LLC2500.01%0Apr 21, 2026
Newedge Advisors, LLC1070.00%0Jun 3, 2026

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Highbridge Capital Management, LLC7.20%13GAug 14, 2025 ↗

Insider tradesForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.